{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:34:00Z","timestamp":1791182040404,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2012,11,15]],"date-time":"2012-11-15T00:00:00Z","timestamp":1352937600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"DOI":"10.1038\/cddis.2012.157","type":"journal-article","created":{"date-parts":[[2012,11,15]],"date-time":"2012-11-15T11:05:41Z","timestamp":1352977541000},"page":"e417-e417","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Proteasome inhibition upregulates Bim and induces caspase-3-dependent apoptosis in human mast cells expressing the Kit D816V mutation"],"prefix":"10.1038","volume":"3","author":[{"given":"C","family":"M\u00f6ller Westerberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"H\u00e4gglund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,11,15]]},"reference":[{"key":"BFcddis2012157_CR1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1080\/10428190400010775","volume":"46","author":"P Valent","year":"2005","unstructured":"Valent P, Akin C, Sperr WR, Mayerhofer M, Fodinger M, Fritsche-Polanz R et al. Mastocytosis: pathology, genetics, and current options for therapy. Leuk Lymphoma 2005; 46: 35\u201348.","journal-title":"Leuk Lymphoma"},{"key":"BFcddis2012157_CR2","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","volume":"37","author":"P Valent","year":"2007","unstructured":"Valent P, Akin C, Escribano L, Fodinger M, Hartmann K, Brockow K et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007; 37: 435\u2013453.","journal-title":"Eur J Clin Invest"},{"key":"BFcddis2012157_CR3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1365-2141.2007.06619.x","volume":"138","author":"A Orfao","year":"2007","unstructured":"Orfao A, Garcia-Montero AC, Sanchez L, Escribano L, REMA. Recent advances in the understanding of mastocytosis: the role of KIT mutations. Br J Haematol 2007; 138: 12\u201330.","journal-title":"Br J Haematol"},{"key":"BFcddis2012157_CR4","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1172\/JCI116761","volume":"92","author":"T Furitsu","year":"1993","unstructured":"Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, Koshimizu U et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 1993; 92: 1736\u20131744.","journal-title":"J Clin Invest"},{"key":"BFcddis2012157_CR5","doi-asserted-by":"publisher","first-page":"10560","DOI":"10.1073\/pnas.92.23.10560","volume":"92","author":"H Nagata","year":"1995","unstructured":"Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 1995; 92: 10560\u201310564.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcddis2012157_CR6","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1182\/blood.V99.5.1741","volume":"99","author":"Y Ma","year":"2002","unstructured":"Ma Y, Zeng S, Metcalfe DD, Akin C, Dimitrijevic S, Butterfield JH et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 2002; 99: 1741\u20131744.","journal-title":"Blood"},{"key":"BFcddis2012157_CR7","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/sj.onc.1206120","volume":"22","author":"Y Zermati","year":"2003","unstructured":"Zermati Y, De Sepulveda P, Feger F, Letard S, Kersual J, Casteran N et al. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene 2003; 22: 660\u2013664.","journal-title":"Oncogene"},{"key":"BFcddis2012157_CR8","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1200\/JCO.2002.20.6.1692","volume":"20","author":"MC Heinrich","year":"2002","unstructured":"Heinrich MC, Blanke CD, Druker BJ, Corless CL . Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002; 20: 1692\u20131703.","journal-title":"J Clin Oncol"},{"key":"BFcddis2012157_CR9","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1158\/0008-5472.CAN-05-2050","volume":"66","author":"MM Schittenhelm","year":"2006","unstructured":"Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY et al. Dasatinib (BMS-354825), a dual SRC\/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006; 66: 473\u2013481.","journal-title":"Cancer Res"},{"key":"BFcddis2012157_CR10","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1182\/blood-2005-10-3969","volume":"108","author":"NP Shah","year":"2006","unstructured":"Shah NP, Lee FY, Luo R, Jiang Y, Donker M, Akin C . Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 2006; 108: 286\u2013291.","journal-title":"Blood"},{"key":"BFcddis2012157_CR11","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1182\/blood-2006-04-013805","volume":"109","author":"J Pan","year":"2007","unstructured":"Pan J, Quintas-Cardama A, Kantarjian HM, Akin C, Manshouri T, Lamb P et al. EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation. Blood 2007; 109: 315\u2013322.","journal-title":"Blood"},{"key":"BFcddis2012157_CR12","doi-asserted-by":"publisher","first-page":"3904","DOI":"10.1038\/sj.onc.1210159","volume":"26","author":"O Kosmider","year":"2007","unstructured":"Kosmider O, Denis N, Dubreuil P, Moreau-Gachelin F . Semaxinib (SU5416) as a therapeutic agent targeting oncogenic Kit mutants resistant to imatinib mesylate. Oncogene 2007; 26: 3904\u20133908.","journal-title":"Oncogene"},{"key":"BFcddis2012157_CR13","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1182\/blood-2005-07-3022","volume":"107","author":"KV Gleixner","year":"2006","unstructured":"Gleixner KV, Mayerhofer M, Aichberger KJ, Derdak S, Sonneck K, Bohm A et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood 2006; 107: 752\u2013759.","journal-title":"Blood"},{"key":"BFcddis2012157_CR14","doi-asserted-by":"publisher","first-page":"5342","DOI":"10.1182\/blood-2008-08-175190","volume":"114","author":"KJ Aichberger","year":"2009","unstructured":"Aichberger KJ, Gleixner KV, Mirkina I, Cerny-Reiterer S, Peter B, Ferenc V et al. Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs. Blood 2009; 114: 5342\u20135351.","journal-title":"Blood"},{"key":"BFcddis2012157_CR15","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/j.leukres.2006.04.005","volume":"30","author":"S Verstovsek","year":"2006","unstructured":"Verstovsek S, Akin C, Manshouri T, Quintas-Cardama A, Huynh L, Manley P et al. Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit. Leuk Res 2006; 30: 1365\u20131370.","journal-title":"Leuk Res"},{"key":"BFcddis2012157_CR16","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1182\/blood-2004-12-4771","volume":"106","author":"AS Corbin","year":"2005","unstructured":"Corbin AS, Demehri S, Griswold IJ, Wang Y, Metcalf CA, Sundaramoorthi R et al. In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit. Blood 2005; 106: 227\u2013234.","journal-title":"Blood"},{"key":"BFcddis2012157_CR17","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1182\/blood-2005-06-2433","volume":"108","author":"M Gabillot-Carre","year":"2006","unstructured":"Gabillot-Carre M, Lepelletier Y, Humbert M, de Sepuvelda P, Hamouda NB, Zappulla JP et al. Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells. Blood 2006; 108: 1065\u20131072.","journal-title":"Blood"},{"key":"BFcddis2012157_CR18","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1182\/blood-2004-08-3247","volume":"105","author":"A Tanaka","year":"2005","unstructured":"Tanaka A, Konno M, Muto S, Kambe N, Morii E, Nakahata T et al. A novel NF-kappaB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors. Blood 2005; 105: 2324\u20132331.","journal-title":"Blood"},{"key":"BFcddis2012157_CR19","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1182\/blood-2004-12-4792","volume":"106","author":"C Moller","year":"2005","unstructured":"Moller C, Alfredsson J, Engstrom M, Wootz H, Xiang Z, Lennartsson J et al. Stem cell factor promotes mast cell survival via inactivation of FOXO3a-mediated transcriptional induction and MEK-regulated phosphorylation of the proapoptotic protein Bim. Blood 2005; 106: 1330\u20131336.","journal-title":"Blood"},{"key":"BFcddis2012157_CR20","doi-asserted-by":"publisher","first-page":"18811","DOI":"10.1074\/jbc.M301010200","volume":"278","author":"R Ley","year":"2003","unstructured":"Ley R, Balmanno K, Hadfield K, Weston C, Cook SJ . Activation of the ERK1\/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. J Biol Chem 2003; 278: 18811\u201318816.","journal-title":"J Biol Chem"},{"key":"BFcddis2012157_CR21","doi-asserted-by":"publisher","first-page":"6785","DOI":"10.1038\/sj.onc.1206792","volume":"22","author":"F Luciano","year":"2003","unstructured":"Luciano F, Jacquel A, Colosetti P, Herrant M, Cagnol S, Pages G et al. Phosphorylation of Bim-EL by Erk1\/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene 2003; 22: 6785\u20136793.","journal-title":"Oncogene"},{"key":"BFcddis2012157_CR22","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/0145-2126(88)90050-1","volume":"12","author":"JH Butterfield","year":"1988","unstructured":"Butterfield JH, Weiler D, Dewald G, Gleich GJ . Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res 1988; 12: 345\u2013355.","journal-title":"Leuk Res"},{"key":"BFcddis2012157_CR23","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1046\/j.1365-2567.2003.01559.x","volume":"108","author":"M Sundstrom","year":"2003","unstructured":"Sundstrom M, Vliagoftis H, Karlberg P, Butterfield JH, Nilsson K, Metcalfe DD et al. Functional and phenotypic studies of two variants of a human mast cell line with a distinct set of mutations in the c-kit proto-oncogene. Immunology 2003; 108: 89\u201397.","journal-title":"Immunology"},{"key":"BFcddis2012157_CR24","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1182\/blood-2007-02-073957","volume":"110","author":"M Ekoff","year":"2007","unstructured":"Ekoff M, Kaufmann T, Engstrom M, Motoyama N, Villunger A, Jonsson JI et al. The BH3-only protein Puma plays an essential role in cytokine deprivation induced apoptosis of mast cells. Blood 2007; 110: 3209\u20133217.","journal-title":"Blood"},{"key":"BFcddis2012157_CR25","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/sj.cdd.4401537","volume":"12","author":"J Alfredsson","year":"2005","unstructured":"Alfredsson J, Puthalakath H, Martin H, Strasser A, Nilsson G . Proapoptotic Bcl-2 family member Bim is involved in the control of mast cell survival and is induced together with Bcl-XL upon IgE-receptor activation. Cell Death Differ 2005; 12: 136\u2013144.","journal-title":"Cell Death Differ"},{"key":"BFcddis2012157_CR26","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1007\/s11064-010-0387-9","volume":"36","author":"JK Ko","year":"2011","unstructured":"Ko JK, Choi CH, Kim YK, Kwon CH . The proteasome inhibitor MG-132 induces AIF nuclear translocation through down-regulation of ERK and Akt\/mTOR pathway. Neurochem Res 2011; 36: 722\u2013731.","journal-title":"Neurochem Res"},{"key":"BFcddis2012157_CR27","first-page":"189","volume":"5","author":"A Strasser","year":"2005","unstructured":"Strasser A . The role of BH3-only proteins in the immune system. Nat Rev 2005; 5: 189\u2013200.","journal-title":"Nat Rev"},{"key":"BFcddis2012157_CR28","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/MOH.0b013e3283366c59","volume":"17","author":"A Pardanani","year":"2010","unstructured":"Pardanani A, Tefferi A . Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo Clinic patients and current literature. Curr Opin Hematol 2010; 17: 125\u2013132.","journal-title":"Curr Opin Hematol"},{"key":"BFcddis2012157_CR29","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S0301-472X(03)00112-7","volume":"31","author":"C Akin","year":"2003","unstructured":"Akin C, Brockow K, D\u2019Ambrosio C, Kirshenbaum AS, Ma Y, Longley BJ et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol 2003; 31: 686\u2013692.","journal-title":"Exp Hematol"},{"key":"BFcddis2012157_CR30","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"352","author":"PG Richardson","year":"2005","unstructured":"Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487\u20132498.","journal-title":"N Engl J Med"},{"key":"BFcddis2012157_CR31","doi-asserted-by":"publisher","first-page":"118","DOI":"10.2174\/156800908783769300","volume":"8","author":"M Miasari","year":"2008","unstructured":"Miasari M, Puthalakath H, Silke J . Ubiquitylation and cancer development. Curr Cancer Drug Targets 2008; 8: 118\u2013123.","journal-title":"Curr Cancer Drug Targets"},{"key":"BFcddis2012157_CR32","doi-asserted-by":"publisher","first-page":"7108","DOI":"10.1038\/sj.onc.1206863","volume":"22","author":"Y Dai","year":"2003","unstructured":"Dai Y, Rahmani M, Grant S . Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK\/JNK- and NF-kappaB-dependent process. Oncogene 2003; 22: 7108\u20137122.","journal-title":"Oncogene"},{"key":"BFcddis2012157_CR33","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0002-9440(10)64557-9","volume":"157","author":"LA O\u2019Reilly","year":"2000","unstructured":"O\u2019Reilly LA, Cullen L, Visvader J, Lindeman GJ, Print C, Bath ML et al. The proapoptotic BH3-only protein bim is expressed in hematopoietic, epithelial, neuronal, and germ cells. Am J Pathol 2000; 157: 449\u2013461.","journal-title":"Am J Pathol"},{"key":"BFcddis2012157_CR34","doi-asserted-by":"publisher","first-page":"6172","DOI":"10.1128\/MCB.24.14.6172-6183.2004","volume":"24","author":"R Kuribara","year":"2004","unstructured":"Kuribara R, Honda H, Matsui H, Shinjyo T, Inukai T, Sugita K et al. Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors. Mol Cell Biol 2004; 24: 6172\u20136183.","journal-title":"Mol Cell Biol"},{"key":"BFcddis2012157_CR35","doi-asserted-by":"publisher","first-page":"9436","DOI":"10.1158\/0008-5472.CAN-05-0972","volume":"65","author":"KJ Aichberger","year":"2005","unstructured":"Aichberger KJ, Mayerhofer M, Krauth MT, Vales A, Kondo R, Derdak S et al. Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR\/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds. Cancer Res 2005; 65: 9436\u20139444.","journal-title":"Cancer Res"},{"key":"BFcddis2012157_CR36","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1111\/j.1398-9995.2006.01213.x","volume":"61","author":"M Gulliksson","year":"2006","unstructured":"Gulliksson M, Palmberg L, Nilsson G, Ahlstedt S, Kumlin M . Release of prostaglandin D2 and leukotriene C4 in response to hyperosmolar stimulation of mast cells. Allergy 2006; 61: 1473\u20131479.","journal-title":"Allergy"},{"key":"BFcddis2012157_CR37","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/j.1365-2567.1996.tb00020.x","volume":"88","author":"G Nilsson","year":"1996","unstructured":"Nilsson G, Blom T, Harvima I, Kusche-Gullberg M, Nilsson K, Hellman L . Stem cell factor-dependent human cord blood derived mast cells express alpha- and beta-tryptase, heparin and chondroitin sulphate. Immunology 1996; 88: 308\u2013314.","journal-title":"Immunology"}],"container-title":["Cell Death & Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/cddis2012157.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/cddis2012157","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cddis2012157.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T23:48:07Z","timestamp":1672962487000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cddis2012157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,15]]},"references-count":37,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2012,11]]}},"alternative-id":["BFcddis2012157"],"URL":"https:\/\/doi.org\/10.1038\/cddis.2012.157","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,15]]},"assertion":[{"value":"7 June 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2012","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2012","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2012","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}